Plasma protein risk scores for mild cognitive impairment and Alzheimer’s disease in the Framingham heart study

by Clinical Neuropsychologist | Saturday, March 29, 2025 | Dementia

Abstract INTRODUCTION It is unclear whether aggregated plasma protein risk scores (PPRSs) could be useful in predicting the risks of mild cognitive impairment (MCI) and Alzheimer’s disease (AD). METHODS The Cox proportional hazard model with the Least Absolute...

Accountable care organizations and Medicare payments for residents with ADRD in disadvantaged neighborhoods

by Clinical Neuropsychologist | Saturday, March 29, 2025 | Dementia

Abstract INTRODUCTION Accountable care organizations (ACOs) are well positioned to promote care coordination. However, robust evidence of ACOs’ impact on Medicare payments for residents with Alzheimer’s disease and related dementias (ADRD) in disadvantaged...

Primary care preparedness to care for patients with ADRD: A national survey study

by Clinical Neuropsychologist | Saturday, March 29, 2025 | Dementia

Abstract INTRODUCTION It is unknown how prepared primary care practices are to deliver recommended dementia care. METHODS A nationally representative survey of US primary care practices focused on care delivery processes, including those for patients with...

A look at caregivers for community‐living persons with dementia: Implications for the GUIDE model

by Clinical Neuropsychologist | Saturday, March 29, 2025 | Dementia

Abstract INTRODUCTION Medicare’s new Guiding an Improved Dementia Experience (GUIDE) model funds integrated dementia care and related caregiver supports for community-living persons with dementia (PwD). Caregiver strain is a factor in provider payment and...

Multi‐omics delineate growth factor network underlying exercise effects in an Alzheimer’s mouse model

by Clinical Neuropsychologist | Saturday, March 29, 2025 | Dementia

Abstract INTRODUCTION Physical exercise is a primary defense against age-related cognitive decline and Alzheimer’s disease (AD). METHODS We conducted single-nucleus transcriptomic and chromatin accessibility analyses (snRNA-seq and snATAC-seq) on the hippocampus...

Plasma biomarkers distinguish Boston Criteria 2.0 cerebral amyloid angiopathy from healthy controls

by Clinical Neuropsychologist | Saturday, March 29, 2025 | Dementia

Abstract INTRODUCTION Cerebral amyloid angiopathy (CAA) is characterized by the deposition of beta-amyloid (Aβ) in small vessels leading to hemorrhagic stroke and dementia. This study examined whether plasma Aβ42/40, phosphorylated-tau (p-tau), neurofilament light...